Cancer Genetics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Cherry hill, n.j., june 01, 2022 (globe newswire) -- vyant bio, inc. (“vyant bio” or “company”) (nasdaq: vynt) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. the company's central nervous system (“cns”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. today, vyant bio announced that it has retained the services of skyline corporate communications group, llc (“skyline”) to manage its investor relations and corporate communications activities within the financial community.

Conference call and webcast today at 4:30 pm et

Cherry hill, n.j., may 05, 2022 (globe newswire) -- vyant bio, inc. (“vyant bio”, “company”) (nasdaq: vynt), an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders, announced that jay roberts, chief executive officer, will present at bionj's 12th annual biopartnering conference. one-on-one partnering meetings will be held throughout the week (may 9-13, 2022). an on-demand replay of vyant bio's presentation will be available to registered guests.

Highlights

Cherry hill, n.j. and esch-sur-alzette, luxembourg, march 29, 2022 (globe newswire) -- vyant bio, inc. (“vyant bio”, “company”) (nasdaq: vynt), an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders and organotherapeutics, a developer of proprietary patient-specific organoids that recapitulate parkinson's disease (pd) pathology, announced today they have entered into a collaboration agreement to work toward accelerating the discovery of drugs for the treatment of parkinson's disease.

Vyant Bio, Inc. (NASDAQ:VYNT ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Jay Roberts - Chief Executive Officer Andy LaFrence - Chief Financial Officer Robert Fremeau - Chief Scientific Officer Conference Call Participants Ed White - H.C. Wainwright Michael Mortensen - WestPark Capital Operator Good afternoon, and welcome to the Vyant Bio First Quarter 2022 Earnings Conference Call and Webcast.

Vyant Bio (NASDAQ:VYNT) Inc ended its first quarter with $16.4 million after a busy three months that saw it progress the discovery of small molecule therapeutics to treat neurological diseases. In the period to March 31, 2022, the Cherry Hill, New Jersey-based company implemented an up to $14.5 million at the market financing vehicle with Canaccord Genuity (TSX:CF, LSE:CF) and another equity line of credit facility with Lincoln Park Capital for up to $15 million.

CHERRY HILL, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that an investor conference call and webcast will be hosted on Monday, May 16, 2022.

Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?

Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q4 2021 Results - Earnings Call Transcript

Vyant Bio (NASDAQ:VYNT) Inc ended its 2021 financial year with a beefed-up cash balance of $20.6 million to help the biotechnology company pursue its development of drugs for complex neurodevelopmental and neurodegenerative disorders. The company is focused primarily on the discovery of small molecule therapeutics to treat neurodevelopmental and neurodegenerative diseases for Rett Syndrome, CDKL5 Deficiency Disorder, and familial Parkinson's Disease.

Here's what you need to know about trading penny stocks on March 30th The post Trading Penny Stocks? Top Stock Market News for March 30th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Vyant Bio (NASDAQ:VYNT) Inc said it has entered into a collaboration agreement with OrganoTherapeutics to accelerate the discovery of drugs to treat Parkinson's Disease (PD). The collaboration brings together the companies' expertise in drug discovery using human-derived cells, high-throughput biology and chemistry, and machine learning-based therapeutic design to identify potential drugs to treat PD.

Vyant Bio Inc (NASDAQ: VYNT) and OrganoTherapeutics have entered into a collaboration agreement to work toward accelerating the discovery of drugs for the treatment of Parkinson's Disease. Specific deal terms were not disclosed.

CHERRY HILL, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that an investor conference call and webcast will be hosted on Wednesday, March 30, 2022.